Huya Bioscience

Executive Summary

Huya Bioscience International is a private biopharmaceutical company headquartered in San Diego, with extensive operations in China including eight offices staffed by dedicated scientists. Founded in 2004, the company has positioned itself as a leader in globalizing China's biopharma innovation, amassing one of the largest compound portfolios covering all major therapeutic areas. By bridging Chinese biotech assets with global development and commercialization opportunities, HUYA leverages its deep network and scientific expertise to advance a diversified pipeline of small molecule drugs. The company's strategy focuses on in-licensing promising candidates from Chinese innovators and advancing them through clinical development, particularly in oncology, immunology, and other high-need areas. With a proven track record of partnerships and a robust portfolio, HUYA is well-positioned to deliver novel therapies to patients worldwide. While the company remains private and does not disclose financial details, its extensive pipeline and strategic collaborations underscore its potential for significant value creation. Given the breadth of its portfolio and established presence in both the US and China, HUYA represents a compelling opportunity in the cross-border biotech space.

Upcoming Catalysts (preview)

• Q4 2026Potential Partnership or Licensing Deal for Lead Asset60% success
• H1 2027Clinical Data Readout for Oncology Program50% success
• Q3 2026Series D or Later-Stage Funding Round70% success